Following this discovery, the EORTC-NCIC trial and other studies have shown that MGMT promoter methylation increases progression free survival (PFS) in cases of GBM treated with TMZ and radiotherapy (RT) vs. RT alone (52, 53). Here, MGMT is linked to glioblastoma.